Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 1, January, p. 83–90

doi: 10.17219/acem/64876

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Expression of VEGF₁₆₅b, VEGFR1, VEGFR2 and CD34 in benign and malignant tumors of parotid glands

Katarzyna J. Błochowiak1,A,B,C,D,E,F, Jerzy Sokalski1,C,E,F, Magdalena B. Bodnar2,B,E,F, Dorota Trzybulska3,B,C,E,F, Andrzej K. Marszałek4,B,E,F, Henryk Witmanowski5,C,E,F

1 Department of Oral Surgery, Poznan University of Medical Sciences, Poland

2 Department of Clinical Pathomorphology, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Poland

3 Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poland

4 Department of Pathomorphology, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Poland

5 Department of Physiology, Poznan University of Medical Sciences, Poland

Abstract

Background. Vascular endothelial growth factor (VEGF) is an angiogenic factor and could be involved in the pathogenesis of salivary gland tumors. VEGF exerts its biological function by binding to its receptors, VEGFR1 and VEGFR2. An alternative splice variant of VEGF (VEGFxxxb) is an anti-angiogenic factor. Binding VEGF165b with VEGFR2 results in an impaired angiogenic response. The imbalance of VEGFxxx and VEGFxxxb isoforms can underpin pathological angiogenesis.
Objectives. The purpose of this study was to evaluate and compare the expression of VEGF165b, VEGFR1, VEGFR2, and CD34 in benign and malignant parotid gland tumors and to explore the possible correlations between their expression and clinicopathological features of tumors.
Material and Methods. The study was performed on archived paraffin-embedded tissue samples derived from 70 patients with benign and malignant parotid gland tumors (25 with malignant tumors, 23 with pleomorphic adenoma and 22 with Warthin’s tumor). Immunohistochemical staining of selected tissue sections was performed using monoclonal antibodies. Immunohistochemical staining of selected molecules was used for evaluation of their expression in tissue sections.
Results. There were no statistically significant differences in the expression of the selected proteins localized in the tumor and surgical margin taken from the same patient. Expression of VEGFR2 correlated with VEGF165b in mixed tumors. There was a statistically significant difference in the expression of VEGFR1 in malignant tumors between females and males, and between the expression of VEGFR1 and the score of T classification in malignant tumors.
Conclusion. VEGF165b cannot be treated as a prognostic factor. VEGF receptors correlated with selected clinicopathological data of malignant tumors, indicating their possible role as a prognostic marker. The balance of VEGF isoforms have a limited influence on the development of parotid glands tumors. The correlation between VEGF165b and VEGFR2 in mixed tumors suggests the existence of an additional antiangiogenic pathway in poorly vascularized mixed tumors.

Key words

VEGF, angiogenesis, salivary gland tumors, CD34, Warthin’s tumor

References (23)

  1. Ishibashi H, Shiratuchi T, Nakagawa K, et al. Hypoxia-induced angiogenesis of cultured human salivary gland carcinoma cells enhances vascular endothelial growth factor production and basic fibroblast growth factor release. Oral Oncol. 2001;37:77–83.
  2. Bodnar M, Szylberg Ł, Kaźmierczak W, Marszałek A. Differentiated expression of membrane type metalloproteinases (MMP-14, MMP-15) and pro-MMP2 in laryngeal squamous cell carcinoma. A novel mechanism. J Oral Pathol Med. 2013;42:267–274.
  3. Younes MN, Park YW, Yazici YD, et al. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther. 2006;5:2696–2705.
  4. de Faria PR, Lima RA, Dias FL, et al. Vascular endothelial growth factor and thymidine phosphorylase expression in salivary gland tumors with distinct metastatic behavior. J Oral Pathol Med. 2011;40:456–459.
  5. Swelam W, Ida-Yonemochi H, Maruyama S, Ohshiro K, Cheng J, Saku T. Vascular endothelial growth factor in salivary pleomorphic adenomas: One of the reasons for their poorly vascularized stroma. Virchows Arch. 2005;446:653–662.
  6. Lequerica-Fernández P, Astudillo A, De Vicente JC. Expression of vascular endothelial growth factor in salivary gland carcinomas correlates with lymph node metastasis. Anti Cancer Res. 2007;27:3661–3666.
  7. Tayama M, Furuhata T, Inafuku Y, et al. Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer. World J Gastroenterol. 2011;17:4867–4874.
  8. Dokun AO, Annex BH. The VEGF165b “ICE-o-form” puts a chill on the VEGF story. Circ Res. 2011;109:246–247.
  9. Qiu Y, Ferguson J, Oltean S, et al. Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol. 2010;21:1498–1509.
  10. Nowak DG, Woolard J, Amin EM, et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Science. 2008;121:3487–3495.
  11. Rennel ES, Waine E, Guan H, et al. The endogenous anti-angiogenic VEGF isoform, VEGF 165b inhibits human tumour growth in mice. Br J Cancer. 2008;98:1250–1257.
  12. Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, et al. Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur J Cancer. 2008;44:1883–1894.
  13. Díaz R, Peña C, Silva J, et al. p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int J Cancer. 2008;123:1060–1067.
  14. Kukreja I, Kapoor P, Deshimukh R, Kulkarni V. VEGF and CD34: A correlation between tumor angiogenesis and microvessel density – An immunohistochemical study. J Oral Maxillofac Pathol. 2013;3:367–373.
  15. Muhammadnejad S, Muhammadnejad A, Haddadi M, et al. Correlation of microvessel dentistry with nuclear pleomorphic, mitotic count and vascular invasion in breast and prostate cancers at preclinical and clinical levels. Asian Pac J Cancer Prev. 2013;14:63–68.
  16. Edge SB, Compton CC. The American Joint Committee on cancer the 7th edition of the AJCC cancer staging manual and future of TNM. Ann Surg Oncol. 2010;17:1471–1474.
  17. The Human Protein Atlas. http://www.proteinatlas.org. Accessed January 2 – March 31, 2015.
  18. Burduk PK, Bodnar M, Sawicki P, et al. Expression of metalloproteinases 2 and 9 and tissue inhibitors 1 and 2 as predictors of lymph node metastases in oropharyngeal squamous cell carcinoma. Head Neck. 2015;37:418–422.
  19. McNemar test calculator – GraphPad. http://www.graphpad.com/quickcalcs/McNemar1.cfm. Accessed January 2 – March 31, 2015.
  20. Lim JJ, Kang S, Lee MR, et al. Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J Oral Pathol Med. 2003;32:552–561.
  21. Bae SJ, Kim JW, Kang H, Hwang SG, Oh D, Kim NK. Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C>T) gene and colon cancer in Korea. Anticancer Res. 2008;28(2B):1271–1276.
  22. Tie Z, Bai R, Zhai Z, et al. Single nucleotide polymorphisms in VEGF gene are associatted with an increased risk of osteosarcoma. Int J Clin Exp Pathol. 2014;7(11):8143–8149.
  23. Patel DK, Morton RP. Demographics of benign parotid tumours: Warthin’s tumour versus other benign salivary tumours. Acta Otolaryngol. 2016;136:83–83.
© Wroclaw Medical University